Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06323291 | Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study | completed | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | recruiting | Early Phase 1 | 30 | University of ArizonaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04665947 | First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer | active not recruiting | Early Phase 1 | 30 | University of California, DavisOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04005690 | Targeted Pathway Inhibition in Patients With Pancreatic Cancer | recruiting | Early Phase 1 | 90 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05141643 | Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer | active not recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | recruiting | Early Phase 1 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05438667 | TCR-T Cell Therapy on Advanced Solid Tumors | terminated | Early Phase 1 | 1 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | not yet recruiting | Early Phase 1 | 40 | Lumina Pharmaceuticals IncINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04601428 | Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | terminated | Early Phase 1 | 12 | Koo Foundation Sun Yat-Sen Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06011772 | EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | active not recruiting | Early Phase 1 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05086250 | Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer | completed | Early Phase 1 | 12 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04123574 | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | BioXcel Therapeutics IncINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04993261 | An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors | active not recruiting | Early Phase 1 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04960072 | A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital) | recruiting | Early Phase 1 | 50 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06828328 | A Study of GC203 TIL in PDCA (RJ) | recruiting | Early Phase 1 | 10 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03143270 | A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer | completed | Early Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05041153 | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma | active not recruiting | Early Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07707531 | A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer | recruiting | Early Phase 1 | 10 | Huashan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | not yet recruiting | Early Phase 1 | 6 | Royan InstituteOTHER_GOV | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | not yet recruiting | Early Phase 1 | 80 | Indiana UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06824363 | ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu | recruiting | Early Phase 1 | 34 | University of California, IrvineOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT02891538 | Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients | completed | Early Phase 1 | 51 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05056896 | ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension | active not recruiting | Early Phase 1 | 161 | Massachusetts General HospitalOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07649928 | A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 24 | Ruijin HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04048278 | Lidocaine Infusion in Pancreatic Cancer | recruiting | Early Phase 1 | 46 | University of Illinois at ChicagoOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07318389 | ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | not yet recruiting | Early Phase 1 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07639970 | Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors | not yet recruiting | Early Phase 1 | 20 | Hua PangOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT05245786 | An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | active not recruiting | Early Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04930991 | High Dose Omeprazole in Patients With Pancreatic Cancer(OU202005AJ) | terminated | Early Phase 1 | 25 | University of OklahomaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06122896 | Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals | recruiting | Early Phase 1 | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06937567 | CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04975217 | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | suspended | Early Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05365893 | PHL Treatment in Pancreatic Cancer | active not recruiting | Early Phase 1 | 20 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03594630 | Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer | recruiting | Early Phase 1 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07597759 | Phase IIT Trial of SNA009 | completed | Early Phase 1 | 12 | SmartNuclide BiopharmaINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07597772 | Preliminary Trial of SNA014 for Pancreatic Cancer | recruiting | Early Phase 1 | 12 | SmartNuclide BiopharmaINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07590856 | A Preliminary Efficacy of SNA028 in Patients With Advanced Colorectal Cancer Positive for GPA33 | not yet recruiting | Early Phase 1 | 20 | SmartNuclide BiopharmaINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07128355 | Botensilimab, Balstilimab, and SBRT in Colorectal Cancer | recruiting | Early Phase 1 | 15 | Massachusetts General HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06653010 | Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer(Wondercel-UWD1) | suspended | Early Phase 1 | 30 | Wondercel Biotech (ShenZhen)INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT06653023 | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer(Wondercel-UWD3) | suspended | Early Phase 1 | 60 | Wondercel Biotech (ShenZhen)INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT06675513 | Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer | suspended | Early Phase 1 | 30 | Wondercel Biotech (ShenZhen)INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT06434376 | MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis | enrolling by invitation | Early Phase 1 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07553767 | Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection | not yet recruiting | Early Phase 1 | 156 | Ningbo No.2 HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07487402 | Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03680586 | Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06034197 | Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy | terminated | Early Phase 1 | 9 | Stephan RogallaOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07033689 | Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II) | recruiting | Early Phase 1 | 10 | SONIRE Therapeutics Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05108428 | Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma | active not recruiting | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials